Literature DB >> 19382254

Absence of genotypic drug resistance and presence of several naturally occurring polymorphisms of human immunodeficiency virus-1 CRF06_cpx in treatment-naive patients in Estonia.

Radko Avi1, Kristi Huik, Maarja Sadam, Tonis Karki, Tonu Krispin, Külliki Ainsalu, Piret Paap, Jelena Schmidt, Natalia Nikitina, Irja Lutsar.   

Abstract

All non-B HIV-1 subtypes and circulating recombinant forms (CRFs) are characterized by several polymorphisms in protease (PR) region. In addition, in recent years the increasing use of antiretroviral treatment (ART) has rapidly raised the spread of transmitted drug resistance. We aimed to determine the presence of naturally occurring polymorphisms and transmitted drug resistance mutations (DRMs) in ART naïve HIV-1-positive subjects in Estonia. A total of 115 drug-naive HIV-1-infected subjects (mean age 27 years; 70% male; 65% infected via intravenous drug use and 34% by heterosexual contact) were enrolled. Viral genomic RNA from plasma was directly sequenced in PR, revertase (RT), and envelope (env) regions. Phylogenetic analysis of RT and env regions revealed that 89% and 3% of sequenced viruses belonged to CRF06_cpx and subtype A1, respectively, and 6% were described as unique recombinants (signed A1-06) between CRF06_cpx and subtype A1 viruses. No primary DRMs were found in PR or RT regions indicating the absence of transmitted drug resistance. The most common polymorphisms in the PR region were K14R, M36I, H69K, and L89M seen in 96%, 100%, 99%, and 100%, respectively. The clinical relevance of these polymorphisms in terms of success of ART has to be monitored in future clinical studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19382254     DOI: 10.1002/jmv.21482

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Estonia at the threshold of the fourth decade of the AIDS era in Europe.

Authors:  Kaja-Triin Laisaar; Radko Avi; Jack DeHovitz; Anneli Uusküla
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-11       Impact factor: 2.205

2.  Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010.

Authors:  Radko Avi; Kristi Huik; Merit Pauskar; Valentina Ustina; Tõnis Karki; Eveli Kallas; Ene-Ly Jõgeda; Tõnu Krispin; Irja Lutsar
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-05       Impact factor: 2.205

3.  Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population.

Authors:  Kristi Huik; Radko Avi; Helen Uibopuu; Merit Pauskar; Tõnu Margus; Tõnis Karki; Tõnu Krispin; Piret Kool; Kristi Rüütel; Ave Talu; Katri Abel-Ollo; Anneli Uusküla; Andrew Carrillo; Weijing He; Sunil K Ahuja; Irja Lutsar
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

4.  The prevalence of transmitted drug resistance in newly diagnosed HIV-infected individuals in Croatia: the role of transmission clusters of men who have sex with men carrying the T215S surveillance drug resistance mutation.

Authors:  Ivana Grgic; Snjezana Zidovec Lepej; Maja M Lunar; Mario Poljak; Adriana Vince; Ivana Baca Vrakela; Ana Planinic; Katja Seme; Josip Begovac
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

5.  CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users.

Authors:  Kristi Huik; Maarja Sadam; Tõnis Karki; Radko Avi; Tõnu Krispin; Piret Paap; Kristi Rüütel; Anneli Uusküla; Ave Talu; Katri Abel-Ollo; Irja Lutsar
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

Review 6.  Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes.

Authors:  Allison Langs-Barlow; Elijah Paintsil
Journal:  Viruses       Date:  2014-10-20       Impact factor: 5.048

7.  The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx.

Authors:  Kristi Huik; Pilleriin Soodla; Merit Pauskar; S Michele Owen; Wei Luo; Gary Murphy; Ene-Ly Jõgeda; Eveli Kallas; Heli Rajasaar; Radko Avi; Silvina Masciotra; Irja Lutsar
Journal:  PLoS One       Date:  2019-05-24       Impact factor: 3.240

8.  The global spread of HIV-1 subtype B epidemic.

Authors:  Gkikas Magiorkinis; Konstantinos Angelis; Ioannis Mamais; Aris Katzourakis; Angelos Hatzakis; Jan Albert; Glenn Lawyer; Osamah Hamouda; Daniel Struck; Jurgen Vercauteren; Annemarie Wensing; Ivailo Alexiev; Birgitta Åsjö; Claudia Balotta; Perpétua Gomes; Ricardo J Camacho; Suzie Coughlan; Algirdas Griskevicius; Zehava Grossman; Anders Horban; Leondios G Kostrikis; Snjezana J Lepej; Kirsi Liitsola; Marek Linka; Claus Nielsen; Dan Otelea; Roger Paredes; Mario Poljak; Elizabeth Puchhammer-Stöckl; Jean Claude Schmit; Anders Sönnerborg; Danica Staneková; Maja Stanojevic; Dora C Stylianou; Charles A B Boucher; Georgios Nikolopoulos; Tetyana Vasylyeva; Samuel R Friedman; David van de Vijver; Gioacchino Angarano; Marie-Laure Chaix; Andrea de Luca; Klaus Korn; Clive Loveday; Vincent Soriano; Sabine Yerly; Mauricio Zazzi; Anne-Mieke Vandamme; Dimitrios Paraskevis
Journal:  Infect Genet Evol       Date:  2016-06-02       Impact factor: 3.342

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.